newsfilter
← Latest News
GlobeNewswire·

argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

  • argenx announced a definitive agreement to acquire Unnatural Products (UNP) to integrate macrocyclic peptide discovery with its existing antibody engineering capabilities.
  • The transaction values UNP at up to approximately $1.15 billion, comprising a $550 million upfront cash payment plus up to $595 million in contingent development & regulatory milestones.
  • This deal extends argenx's immunology innovation to enable the development of oral & long-acting medicines for patients with serious immune-mediated diseases.
  • UNP will continue operating from its Santa Cruz, California headquarters as argenx's dedicated site for peptide discovery while retaining its current team & science-first culture.
  • The acquisition is expected to close by the end of 2026, subject to customary closing conditions & regulatory approvals.
  • Morgan Stanley & Co. LLC served as exclusive financial advisor to argenx, while DLA Piper LLP acted as legal advisor to argenx & Latham & Watkins LLP served as legal counsel to UNP.
Company
argenx SE
Keywords
Brussels Stock Exchange:ARGX, argenx SE